CD8A and neoplasm: The FDA recently approved immunohistochemistry (IHC) assays of tumor infiltrating immune cells to predict ICI benefit in patients with NSCLC (51), and higher levels of CD8+ TILs has been associated with higher PFS for NSCLC patients treated with nivolumab (9).